Richard J. Jones
YOU?
Author Swipe
View article: Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.
Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study. Open
Introduction: Graft Failure (GF) is a rare but devastating outcome of HCT. Primary GF (PGF), defined as a failure of neutrophil recovery by Day+28, is straightforward to diagnose. Diagnosing secondary GF (SGF) is more challenging, with its…
View article: Post-allogeneic hematopoietic cell transplantation outcomes are similar after hypomethylating agent/venetoclax and intensive, cytarabine-based remission induction for Acute Myeloid Leukemia when using standardized, contemporary transplant techniques
Post-allogeneic hematopoietic cell transplantation outcomes are similar after hypomethylating agent/venetoclax and intensive, cytarabine-based remission induction for Acute Myeloid Leukemia when using standardized, contemporary transplant techniques Open
Introduction: Since the introduction of hypomethylating agent (HMA) and venetoclax combination therapy for acute myeloid leukemia (AML), retrospective analyses have demonstrated similar outcomes between patients who received this less inte…
View article: A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML
A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML Open
Patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) with high-risk features including TP53 mutations have poor outcomes due to lack of effective therapies. The atypical chemokine surface receptor C-C motif chemokine r…
View article: C-C motif chemokine receptor-like 2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated <i>TP53</i>
C-C motif chemokine receptor-like 2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated <i>TP53</i> Open
Patients with myeloid neoplasms with loss-of-function TP53 mutations and erythroid differentiation have poor outcomes, and a better understanding of disease biology is required. Upregulation of interferon-γ (IFN-γ) signaling has been assoc…
View article: Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML Open
View article: Impact of transplant conditioning, <i>NPM1</i> mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia
Impact of transplant conditioning, <i>NPM1</i> mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia Open
We conducted a post hoc analysis of data from Blood and Marrow Transplant Clinical Trials Network 1506 (MORPHO), a randomized trial of gilteritinib vs placebo as posttransplantation maintenance for patients with FLT3-ITD–mutated acute myel…
View article: Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703 Open
Allogeneic hematopoietic cell transplant (allo-HCT) is underutilized in adults aged ≥70 years. Morbidity, often driven by graft-versus-host disease (GVHD), is considered a major barrier to its use. The BMT CTN 1703 trial (ClinicalTrials.go…
View article: CCRL2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated <i>TP53</i>
CCRL2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated <i>TP53</i> Open
Patients with myeloid neoplasms with loss-of-function TP53 mutations and erythroid differentiation have poor outcomes, and a better understanding of disease biology is required. Upregulation of interferon-γ (IFN-γ) signaling has been assoc…
View article: Measurable residual disease and posttransplantation gilteritinib maintenance for patients with <i>FLT3-ITD</i>–mutated AML
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with <i>FLT3-ITD</i>–mutated AML Open
BMT CTN (Blood and Marrow Transplant Clinical Trials Network) 1506 (“MORPHO”) was a randomized study of gilteritinib compared with placebo as maintenance therapy after hematopoietic cell transplantation (HCT) for patients with FLT3-ITD–mut…
View article: Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703 Open
The BMT CTN 1703 phase III trial confirmed that graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) results in superior GVHD-free, relapse-free s…
View article: Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma
Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma Open
Patients with relapsed classic Hodgkin lymphomas (cHLs) receive salvage therapy with immune checkpoint inhibitors (ICIs) or chemotherapy (no-ICI). Patients responding to therapy often undergo consolidation with allogeneic blood or marrow t…
View article: Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy?
Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy? Open
Sickle cell disease (SCD) is the most common inherited blood disease. Disease-modifying therapy and supportive care have improved the survival of children with SCD in the United States and Europe. Yet, adults with SCD continue to have high…
View article: Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies
Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies Open
Allogeneic blood and marrow transplantation (alloBMT) is increasingly being used in older patients with blood cancer. Aging is associated with an increasing incidence of clonal hematopoiesis (CH). Although the effects of donor CH on alloBM…
View article: Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i> Open
PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 ( FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after…
View article: A phase I study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer
A phase I study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer Open
Hemay022 at the dose of 500 mg once daily was well tolerated. The pharmacokinetic properties and encouraging anti-tumor activities of Hemay022 in advanced breast cancer patients warranted further evaluation of Hemay022 for treating breast …
View article: Outcome heterogeneity of <i>TP53</i>-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation
Outcome heterogeneity of <i>TP53</i>-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation Open
Not available.
View article: Persistent<i>IDH</i>mutations are not associated with increased relapse or death in patients with<i>IDH</i>-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide
Persistent<i>IDH</i>mutations are not associated with increased relapse or death in patients with<i>IDH</i>-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide Open
The presence of measurable residual disease (MRD) prior to an allogeneic hematopoietic transplant (alloHCT) in Acute Myeloid Leukemia (AML) has been shown to be associated with an increased risk of post-transplant relapse. Since the Isocit…
View article: P1269: PRIMARY GRAFT FAILURE INCIDENCE, RISK FACTORS, AND OUTCOMES IN PATIENTS UNDERGOING NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE
P1269: PRIMARY GRAFT FAILURE INCIDENCE, RISK FACTORS, AND OUTCOMES IN PATIENTS UNDERGOING NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE Open
Topic: 22. Stem cell transplantation - Clinical Background: Primary graft failure (PGF) is a major complication of alloHCT that results in significant morbidity and mortality. Factors previously associated with PGF include HLA disparity, A…
View article: Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration
Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration Open
Haploidentical donors offer a potentially readily available donor, especially for non-White patients, for hematopoietic cell transplantation (HCT). In this North American collaboration, we retrospectively analyzed outcomes of first HCT usi…
View article: Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis Open
Among patients undergoing allogeneic HLA-matched HSCT with reduced-intensity conditioning, GVHD-free, relapse-free survival at 1 year was significantly more common among those who received cyclophosphamide-tacrolimus-mycophenolate mofetil …
View article: Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes
Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes Open
The measurable residual disease (MRD) assessment provides an attractive predictor of allogeneic hematopoietic cell transplnat (alloHCT) outcomes. Cell-free DNA (cfDNA) has been applied to diagnosis, early detection, and disease burden moni…
View article: Alternative donor BMT with post-transplant cyclophosphamide as initial therapy for acquired severe aplastic anemia
Alternative donor BMT with post-transplant cyclophosphamide as initial therapy for acquired severe aplastic anemia Open
Severe aplastic anemia (SAA) is a marrow failure disorder with high morbidity and mortality. It is treated with bone marrow transplantation (BMT) for those with fully matched donors or immunosuppressive therapy (IST) for those who lack suc…
View article: Supplementary Table 2 from Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA
Supplementary Table 2 from Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA Open
PDF file, 67K, IC50 values of MI63R and NutlinR cell lines to chemotherapy agents.
View article: Supplementary Figure Legends from Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia
Supplementary Figure Legends from Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia Open
Supplementary Figure Legends
View article: Supplementary Figures from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Supplementary Figures from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191 Open
Supplementary Figure 1. BCWM. 1 (upper panel) and MWCL-1 cells (lower panel) were seeded in 96-well plates (20,000 cells/well) and treated with increasing concentrations (0.0, 0.15, 0.3125, 0.625, 1.25, 2.5, 5.0 ï�M) of the indicated IRAK…
View article: Supplementary Data from Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damage–Independent p53 Phosphorylation in Mantle Cell Lymphoma
Supplementary Data from Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damage–Independent p53 Phosphorylation in Mantle Cell Lymphoma Open
Supplementary Data from Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damage–Independent p53 Phosphorylation in Mantle Cell Lymphoma
View article: Data from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Data from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191 Open
Purpose:Waldenström's macroglobulinemia is an incurable lymphoproliferative disorder driven by an L265P mutation in the myeloid differentiation primary response gene 88 (MYD88), which activates downstream NF-κB signaling through the…
View article: Combination Indices (CI) of LEN, THAL or POM in combination with GCV at 7 days. from Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression
Combination Indices (CI) of LEN, THAL or POM in combination with GCV at 7 days. from Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression Open
Combination indices of LEN, THAL or POM in combination with GCV.
View article: Data from Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies
Data from Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies Open
FMS-like tyrosine kinase-3 (FLT3) tyrosine kinase inhibitors (TKI) have been tested extensively to limited benefit in acute myeloid leukemia (AML). We hypothesized that FLT3/internal tandem duplication (ITD) leukemia cells exhibit mechanis…
View article: CCR Translation for the Article from Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes
CCR Translation for the Article from Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes Open
CCR Translation for the Article from Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes